About Polaris

Polaris Group is a multinational pharmaceutical company specializes in the research and development of novel drugs to treat cancer.

The company's lead therapeutic, ADI-PEG 20, is a novel biologic that is in late stage of clinical development. It has been tested in more than twenty clinical trials globally for a wide variety of cancers, such as hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, non-Hodgkin’s lymphoma and others.

As a fully integrated company, Polaris is engaged in applying protein structure-based drug design technology to develop novel drug candidates for cancers, conducting clinical studies at top-tier cancer centers worldwide, and manufacturing all clinical materials in-house at cGMP facilities in Northern California.